Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Germany: Petinutin.

North America

Canada: Celontin; USA: Celontin.

Drug combinations


Methsuximide: C~12~H~13~NO~2~. Mw: 203.24. (1) 2,5-Pyrrolidinedione,1,3-dimethyl-3-phenyl-, (±)-; (2)(±)-N,2-Dimethyl-2-phenylsuccinimide. CAS-77-41-8.

Pharmacologic Category

Anticonvulsants; Succinimides. (ATC-Code: N03AD03).

Mechanism of action

Increases seizure threshold and suppresses paroxysmal spike-and-wave pattern in absence seizures. Depresses nerve transmission in motor cortex.

Therapeutic use

Control of absence (petit mal) seizures refractory to other drugs.

Pregnancy and lactiation implications

Safe use of methsuximide during pregnancy or lactation not established.

Unlabeled use

Partial complex (psychomotor) seizures.


Hypersensitivity to succinimides or any component of the formulation.

Warnings and precautions

Succinimides associated with severe blood dyscrasias; also with cases of systemic lupus erythematosus. Use with caution in hepatic impairment, and in renal impairment. Effects with other sedative drugs or ethanol may be potentiated. Must be used in combination with other anticonvulsants in both absence and tonic-clonic seizures. May increase tonic-clonic seizures in mixed seizure disorders. Therapy should be withdrawn gradually.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart